Bharat Book Bureau

“Critical Care Market to 2017 – Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles” provides in-depth analysis of drivers and barriers that impact the global critical care market. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. This includes treatment usage patterns, average annual cost of therapy and market size forecast until 2017 for the key geographies as well as the leading therapeutic segments.

The report also provides information on the R&D product pipeline and explores the competitive landscape, including major players in the critical care market. Finally, the report includes analysis on mergers and acquisitions (M&As) in the critical care market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. industry analysis reports

– Data and analysis on the critical care market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
– Annualized market data for the critical care market that includes markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2002 to 2010, with forecasts to 2017
– Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume and treatment usage patterns such as disease population, diagnosis population and prescription population
– Key drivers and restraints that have had a significant impact on the market
– The competitive landscape of the global critical care market, including top companies benchmarking. The key companies studied in this report are CSL, Octapharma, Baxter, Grifols and LFB
– Key M&A activities that took place in 2010 and 2011 in the critical care market

Reasons to buy
– Align your product portfolio to the markets with high growth potential
– Build effective strategies to launch their pipeline products by identifying potential geographies
– Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
– Develop key strategic initiatives by studying the key strategies of top competitors
– Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication
– Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
– Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

Companies Mentioned
Hanall Pharmaceutical
Patrys Limited
F. Hoffmann-La Roche Ltd.
Mirna Therapeutics
Aphios Corporation

For more information kindly visit :
Critical Healthcare Market to 2017 – Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles


Contact us at :

Bharat Book Bureau
Tel: 09221586973
Follow us on twitter:!/Sandhya3B

Author :